IR信息Notice Regarding Results of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)

IR信息Announcement of Extraordinary Gains (Gain on Sale of Investment Securities)

IR信息Summary of Q&A Session for Management Presentation on Feb 27 2026

IR信息Notice Concerning Change in Equity-Method Affiliate (Becoming a Consolidated Subsidiary)

IR信息Presentation Materials for Management Presentation on Feb 27 2026 with Script

IR信息(Amendment) Notice Regarding Amendment to “Notice Regarding Commencement of Tender Offer for Share Certificates, Etc. of KAINOS Laboratories, Inc. (Securities Code: 4556)” and Public Notice of Commencementof Tender Offer Dueto Filingof Amendment Statement

IR信息Notice of Formulation of Management Plan “Mission 2030” Phase 2 (FY2026–FY2028)

IR信息Presentation Material for Management Presentation on Feb 27th 2026

IR信息Notice of Commencement of Consideration of Spin-off of Styrene-Related Businesses

CSR信息First-time Selection as an Environmentally Sustainable Company at the ESG Finance Awards Japan

IR信息FY2025 Third Quarter Financial Results Presentation Materials with Script

IR信息Notice Regarding Recognition of Extraordinary Losses

IR信息Notice Regarding Personnel Changes in Executive Officers

IR信息FY2025 Third Quarter Financial Results Presentation Materials

IR信息FY2025 Third Quarter Summary of Consolidated Financial Results

CSR信息Awarded “A-” for Climate Change and “A” rating for Water Security in CDP 2025

产品信息Development of an ESD (endoscopic submucosal dissection) simulator model for early-stage gastrointestinal neoplasms～Results of the third “Medical Rising STAR” industry-academia collaboration project～

信息社长新年致辞（节选自新年训辞）